Clinical Trial Detail

NCT ID NCT02130557
Title A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Avillion Development 1 Limited
Indications

chronic myeloid leukemia

Therapies

Bosutinib

Imatinib

Age Groups: adult

No variant requirements are available.